Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 8:12:867684.
doi: 10.3389/fonc.2022.867684. eCollection 2022.

Leukemia Stem Cell Frequency at Diagnosis Correlates With Measurable/Minimal Residual Disease and Impacts Survival in Adult Acute Myeloid Leukemia

Azza M Kamel  1 , Nahla M Elsharkawy  1 , Eman Z Kandeel  1 , Marwa Hanafi  1 , Mohammed Samra  2 , Randa A Osman  1
Affiliations

Leukemia Stem Cell Frequency at Diagnosis Correlates With Measurable/Minimal Residual Disease and Impacts Survival in Adult Acute Myeloid Leukemia

Azza M Kamel et al. Front Oncol. .

Abstract

Acute myeloid leukemia (AML) is a heterogenous disease in which the initiation and maintenance of the malignant clone is blamed on a rare population of leukemia stem cells (LSCs). The persistence of such a malignant population is referred to as measurable/minimal residual disease (MRD). Evaluation of MRD is the gold standard for follow-up of therapy and constitutes an independent prognostic parameter. As LSCs are the main contributor to the persistence of MRD, then MRD should correlate with the bulk of LSCs at the individual case level. MRD is measured at defined time points during therapy. However, LSCs can be evaluated at diagnosis, which ensures the advantage of early prediction of high-risk patients and allows for early therapeutic decisions. Using two simple four-color monoclonal antibody combinations (CD38/CD123/CD34/CD45 and CD90/CD133/CD45/CD33) and the prism function of the Coulter Navios flow cytometer, the frequency of LSC subsets was evaluated in 84 newly diagnosed adult AML patients. For each panel, 16 possible combinations were detected. Our results showed that there was extreme variability in the percentage of the LSC fraction between different cases, as well as at the individual case level. For each LSC subset, the median value was used to divide cases into low and high expressors. LSC subsets that showed an impact on overall survival (OS) and disease-free survival (DFS) included CD123+, CD 123+/CD34-, CD34-/CD38+/CD123+, CD34+/CD38-/CD123+, CD133+, and CD133+/CD33-. On multivariate analysis, only CD123 (p ≤ 0.001, SE = 0.266, HR = 2.8, 95% CI = 1.74.7) and CD133+/CD33- (p = 0.017, SE = 0.263, HR = 1.9, 95% CI = 1.1-3.1) retained their significance for OS. Likewise, only CD34+/CD38-/CD123+ (p ≤ 0.001, HR 2.3, SE: 0.499, 95% CI: 2.4-17.4) and CD133 (p = 0.015, HR 2.3, SE 0.34, 95% CI: 1.2-4.4) retained their statistical significance for DFS. The LSC frequency at diagnosis showed a moderate to strong correlation with MRD status at day 14 and day 28. In conclusion, the level of LSCs at diagnosis correlated with MRD status at day 14 and day 28 in AML patients and had a deleterious impact on OS and DFS. It may be used as an early marker for high-risk patients allowing for early therapeutic decisions.

Keywords: AML; CD123; CD133; LSC; MRD.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Impact of leukemia stem cell marker(s) at diagnosis on overall survival in 80 adult acute myeloid leukemia patients by using panel CD38 FITC/CD123PE/CD34ECD/CD45PE-PC5.
Figure 2
Figure 2
Impact of leukemia stem marker(s) on overall survival in 80 adult acute myeloid leukemia patients at diagnosis by using panel CD90 FITC/CD133PE/CD45ECD/CD33PE-PC5.
Figure 3
Figure 3
Impact of leukemia stem cell marker(s) at diagnosis on disease-free survival in 80 adult acute myeloid leukemia patients by using panel CD38 FITC/CD123PE/CD34ECD/CD45PE-PC5.
Figure 4
Figure 4
Impact of leukemia stem cell marker(s) at diagnosis on disease-free survival in 80 adult acute myeloid leukemia patients by using panel CD90 FITC/CD133PE/CD45ECD/CD33PE-PC5.
See this image and copyright information in PMC

References

    1. Matthes TH, Hauwel M. Minimal Residual Disease Monitoring: The New Standard for Treatment Evaluation of Haematological Malignancies? Swiss Flow Cytometry School, Haematology Service and Clinical P Athology Service, Geneva University Hospital, Switzerland. Swiss Med Wkly (2014) 144:w13907. doi: 10.4414/smw.2014.13907 - DOI - PubMed
    1. van Dongen JJ, van der Velden VH, Brüggemann M, Orfao A. Minimal Residual Disease Diagnostics in Acute Lymphoblastic Leukemia: Need for Sensitive, Fast, and Standardized Technologies. Blood (2015) 125:3996–4009. doi: 10.1182/blood-2015-03-580027 - DOI - PMC - PubMed
    1. Athale UH, Gibson PJ, Bradley NM, Malkin DM, Hitzler J, POGO MRD Working Group . Minimal Residual Disease and Childhood Leukemia: Standard of Care Recommendations From the Pediatric Oncology Group of Ontario MRD Working Group. Pediatr Blood Cancer (2016) 63:973–82. doi: 10.1002/pbc.25939 - DOI - PubMed
    1. Ravandi F, Jorgensen JL, O’Brien SM, Jabbour E, Thomas DA, Borthakur G, et al. . Minimal Residual Disease Assessed by Multi-Parameter Flow Cytometry is Highly Prognostic in Adult Patients With Acute Lymphoblastic Leukaemia. Br J Haematol (2016) 172:392–400. doi: 10.1111/bjh.13834 - DOI - PMC - PubMed
    1. Brüggemann M, Kotrova M. Minimal Residual Disease in Adult ALL: Technical Aspects and Implications for Correct Clinical Interpretation. Hematol Am Soc Hematol Educ Program (2017) 2017:13–21. doi: 10.1182/asheducation-2017.1.13 - DOI - PMC - PubMed